

WOAH Reference Laboratory Reports Activities 2023

Activities in 2023

Laboratory Information

| | |
|--------------------------------------------------------------------------------------------|----------------------------------------|
| Name of disease (or topic) for which you are a designated WOA Reference Laboratory: | Swine influenza |
| Address of laboratory: | Via Bianchi 9 25124 Brescia |
| Tel.: | +39 (0)52129.37.33 |
| E-mail address: | chiara.chiapponi@izsler.it |
| Website: | |
| Name (including Title) of Head of Laboratory (Responsible Official): | Dr. Giorgio Varisco, General Director |
| Name (including Title and Position) of WOA Reference Expert: | Dr. Chiara Chiapponi, senior scientist |
| Which of the following defines your laboratory? Check all that apply: | Governmental |

TOR1: DIAGNOSTIC METHODS

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.?

(Not for quality control, proficiency testing or staff training)

Yes

| Diagnostic Test | Indicated in WOA Manual (Yes/No) | Total number of test performed last year | |
|--------------------------------------|----------------------------------------|------------------------------------------|-----------------|
| | | Nationally | Internationally |
| Indirect diagnostic tests | | | |
| Hemagglutination inhibition test | | 7400 | 2900 |
| ELISA anti-NP | | 790 | 100 |
| Direct diagnostic tests | | | |
| Real-time RT-PCR | | 3000 | 17 |
| Multiplex RT-PCR for subtyping | | 135 | 5 |
| Cell culture isolation | | 180 | 0 |
| Embryonated chicken eggs inoculation | | 100 | 0 |
| NGS full genome sequencing | | 100 | 0 |

TOR2: REFERENCE MATERIAL

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by WOA?

No

3. Did your laboratory supply standard reference reagents (nonWOA-approved) and/or other diagnostic reagents to WOA Members?

Yes

| TYPE OF REAGENT AVAILABLE | RELATED DIAGNOSTIC TEST | PRODUCED/ PROVIDE | AMOUNT SUPPLIED NATIONALLY (ML, MG) | AMOUNT SUPPLIED INTERNATIONALLY (ML, MG) | NO. OF RECIPIENT WOA MEMBER COUNTRIES | COUNTRY OF RECIPIENTS |
|------------------------------|-------------------------|-------------------|-------------------------------------|------------------------------------------|---------------------------------------|-----------------------|
| Swine hyperimmune serum H1N1 | HI TEST | provided | 0 | 1.5 ML | 1 | NORWAY, |

| | | | | | | |
|-------------------------------------------|---------------------------------------------------------------------------|----------|---|--------|---|-----------------|
| Swine hyperimmune serum H1N2 | HI TEST | provided | 0 | 1.5 ML | 1 | NORWAY, |
| Swine hyperimmune serum H3N2 | HI TEST | provided | 0 | 1.5 ML | 1 | NORWAY, |
| Swine hyperimmune serum H1N1 pdm | HI TEST | provided | 0 | 1.5 ML | 1 | NORWAY, |
| Swine influenza virus H1N1 (clade 1C) | HI TEST | provided | 0 | 3 | 1 | SWEDEN, |
| Swine influenza virus H1N1 (clade 1A) | HI TEST | provided | 0 | 3 | 1 | SWEDEN, |
| Swine influenza virus (multiple subtypes) | HI characterization against the relevant ferret antisera (CVV evaluation) | provided | 0 | 7 ML | 1 | UNITED KINGDOM, |

4. Did your laboratory produce vaccines?

No

5. Did your laboratory supply vaccines to WOAHP Members?

No

TOR3: NEW PROCEDURES

6. Did your laboratory develop new diagnostic methods for the designated pathogen or disease?

No

7. Did your laboratory validate diagnostic methods according to WOAHP Standards for the designated pathogen or disease?

No

8. Did your laboratory develop new vaccines for the designated pathogen or disease?

No

9. Did your laboratory validate vaccines according to WOAHP Standards for the designated pathogen or disease?

No

TOR4: DIAGNOSTIC TESTING FACILITIES

10. Did your laboratory carry out diagnostic testing for other WOAHP Members?

Yes

| NAME OF WOAHP MEMBER COUNTRY SEEKING ASSISTANCE | DATE | WHICH DIAGNOSTIC TEST USED | NO. SAMPLES RECEIVED FOR PROVISION OF DIAGNOSTIC SUPPORT | NO. SAMPLES RECEIVED FOR PROVISION OF CONFIRMATORY DIAGNOSES |
|----------------------------------------------------|------------|----------------------------|----------------------------------------------------------------|--------------------------------------------------------------------|
| CYPRUS | 2023-03-31 | ELISA (kit ID VET) | 25 | 0 |
| CYPRUS | 2023-11-30 | ELISA (kit ID VET) | 25 | 0 |
| CYPRUS | 2023-03-31 | HI TEST | 164 | 0 |
| CYPRUS | 2023-04-30 | HI TEST | 10 | 0 |
| CYPRUS | 2023-05-31 | HI TEST | 327 | 0 |
| CYPRUS | 2023-10-31 | HI TEST | 208 | 0 |
| CYPRUS | 2023-04-30 | PCR multiplex | 1 | 0 |
| CYPRUS | 2023-05-30 | PCR multiplex | 2 | 0 |
| CYPRUS | 2023-09-30 | PCR multiplex | 1 | 0 |
| CYPRUS | 2023-12-31 | PCR multiplex | 1 | 0 |
| CYPRUS | 2023-03-31 | real-time PCR | 1 | 0 |
| CYPRUS | 2023-04-30 | real-time PCR | 2 | 0 |
| CYPRUS | 2023-05-31 | real-time PCR | 8 | 0 |
| CYPRUS | 2023-06-30 | real-time PCR | 2 | 0 |
| CYPRUS | 2023-09-30 | real-time PCR | 1 | 0 |
| CYPRUS | 2023-12-31 | real-time PCR | 1 | 0 |
| GREECE | 2023-01-31 | HI TEST | 404 | 0 |
| GREECE | 2023-02-28 | HI TEST | 44 | 0 |
| GREECE | 2023-03-31 | HI TEST | 372 | 0 |

| | | | | |
|--------|------------|---------|-----|---|
| GREECE | 2023-04-30 | HI TEST | 56 | 0 |
| GREECE | 2023-05-31 | HI TEST | 120 | 0 |
| GREECE | 2023-06-30 | HI TEST | 609 | 0 |
| GREECE | 2023-09-30 | HI TEST | 172 | 0 |
| GREECE | 2023-10-31 | HI TEST | 200 | 0 |
| GREECE | 2023-11-30 | HI TEST | 24 | 0 |
| GREECE | 2023-12-31 | HI TEST | 108 | 0 |
| GREECE | 2023-03-31 | HI TEST | 1 | 0 |

11. Did your laboratory provide expert advice in technical consultancies on the request of an WOA Member?

Yes

| NAME OF THE WOA MEMBER COUNTRY RECEIVING A TECHNICAL CONSULTANCY | PURPOSE | HOW THE ADVICE WAS PROVIDED |
|------------------------------------------------------------------|----------------------------------------------|-----------------------------|
| NORWAY | Consulting HI test | mail |
| SWEDEN | Consulting HI test | mail |
| AUSTRIA | Consulting sampling | mail |
| SPAIN | Consulting HI test | mail |
| FINLAND | SOPs for virus isolation, consulting HI test | mail |
| GREECE | SOP for diagnostic | COST STSM |
| KOSOVO | training | presentation |
| ROMANIA | training | Lab hosting |

TOR5: COLLABORATIVE SCIENTIFIC AND TECHNICAL STUDIES

12. Did your laboratory participate in international scientific studies in collaboration with WOA Members other than the own?

Yes

| Title of the study | Duration | PURPOSE OF THE STUDY | PARTNERS (INSTITUTIONS) | WOAH MEMBER COUNTRIES INVOLVED OTHER THAN YOUR COUNTRY |
|----------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Understanding the dynamics and evolution of swine influenza viruses in Europe: relevance for improved intervention and sustainable pig production (PIGE) | 2021-2024 | ICRAD Co-Funded Project: Research Area 1: Improved understanding of epidemic and emerging infectious animal diseases | French Agency for Food, Environmental and Occupational Health & Safety (ANSES), Animal and Plant Health Agency (APHA),Friedrich-Loeffler-Institut (FLI), University of Copenhagen (UCPH),Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia Romagna (IZSLER), Universitat Autònoma de Barcelona (UAB) | DENMARK FRANCE GERMANY SPAIN UNITED KINGDOM |
| Swine influenza data for OFFLU contribution to WHO vaccine composition meeting | annual | To share animal influenza data with WHO in order to assist with selection of the most appropriate viruses for human vaccines, which can include animal viruses that present a potential to emerge into pandemic threats. | OFFLU partners | |
| COST Action CA21132, European Swine Influenza Network (ESFLU) | 2022-2026 | ESFLU gathers 76 experts in an interdisciplinary One Health approach. The Action will advance scientific knowledge concerning swIAV, improve disease surveillance and management capabilities, | Medicine, AUT;Faculty of Veterinary Medicine;ANSES Ploufragan-Plouzané-Niort Laboratory;Finnish Food Authority Ruokavirasto;University of Helsinki;Animal and Plant Health Agency;Aristotle University of Thessaloniki;Croatian veterinary Institute;Istituto zooprofilattico sperimentale delle venezie;Istituto Zooprofilattico Sperimentale della Lombardia ed Emilia Romagna;Teagasc;Norwegian Veterinary Institute;The Norwegian Veterinary Institute;Utrecht University;Royal GD Animal Health;FCIENCIAS.ID - ASSOCIACAO PARA A INVESTIGACAO E DESENVOLVIMENTO DE CIENCIAS;Faculty | ALBANIA AUSTRIA BELGIUM BOSNIA AND HERZEGOVINA BULGARIA CROATIA CZECH REPUBLIC DENMARK FINLAND FRANCE GERMANY GREECE IRELAND MONTENEGRO NORWAY POLAND PORTUGAL |

| | | | | |
|--|--|---------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|
| | | benefit pork production and reduce risks to both animal and human health. | of Veterinary Medicine of the University of Lisbon;Institute for Research and development in Montanology;University Of Agricultural Sciences and Veterinary Medicine;Department of Animal Health and Antimicrobial Strategies;University of Ljubljana, Veterinary faculty;University of Sarajevo - Veterinary Faculty;Veterinary faculty, Veterinary institute;Diagnostic Veterinary Laboratory;Institute of Veterinary Medicine of Serbia;Scientific Veterinary Institute "Novi Sad";University of Ghent | ROMANIA SERBIA SLOVAKIA SPAIN SWEDEN SWITZERLAND THE NETHERLANDS UNITED KINGDOM |
|--|--|---------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|

13. In exercising your activities, have you identified any regulatory research needs* relevant for WOA?

TOR6: EPIZOOLOGICAL DATA

14. Did your Laboratory collect epidemiological data relevant to international disease control?

Yes

IF THE ANSWER IS YES, PLEASE PROVIDE DETAILS OF THE DATA COLLECTED:

Viral strains are isolated for genetic and antigenic characterization. Origin and date of sampling are collected

15. Did your laboratory disseminate epidemiological data that had been processed and analysed?

Yes

IF THE ANSWER IS YES, PLEASE PROVIDE DETAILS OF THE DATA COLLECTED:

Sequencing data, origin and date of sampling (OFFLU-VCM)

16. What method of dissemination of information is most often used by your laboratory? (Indicate in the appropriate box the number by category and list the details in the box)

a) Articles published in peer-reviewed journals:

3

López-Valiñas Á, Valle M, Wang M, Darji A, Cantero G, Chiapponi C, Segalés J, Ganges L, Núñez JI. Vaccination against swine influenza in pigs causes different drift evolutionary patterns upon swine influenza virus experimental infection and reduces the likelihood of genomic reassortments. *Front Cell Infect Microbiol.* 2023 Mar 13;13:1111143. doi: 10.3389/fcimb.2023.1111143. PMID: 36992684; PMCID: PMC10040791.

van Diemen PM, Byrne AMP, Ramsay AM, Watson S, Nunez A, V Moreno A, Chiapponi C, Foní E, Brown IH, Brookes SM, Everett HE. Interspecies Transmission of Swine Influenza A Viruses and Human Seasonal Vaccine-Mediated Protection Investigated in Ferret Model. *Emerg Infect Dis.* 2023 Sep;29(9):1798-1807. doi: 10.3201/eid2909.230066. PMID: 37610158; PMCID: PMC10461666.

López-Valiñas Á, Valle M, Pérez M, Darji A, Chiapponi C, Ganges L, Segalés J, Núñez JI. Genetic diversification patterns in swine influenza A virus (H1N2) in vaccinated and nonvaccinated animals. *Front Cell Infect Microbiol.* 2023 Sep 15;13:1258321. doi: 10.3389/fcimb.2023.1258321. PMID: 37780850; PMCID: PMC10540852.

Maksimović Zorić J, Miličević V, Veljović L, Radosavljević V, Kureljušić B, Stevančević O, Chiapponi C. Genetic analysis of influenza A viruses of swine from commercial farms in Serbia. *Vet Ital.* 2023 Jul 31;59(2). doi: 10.12834/VetIt.2712.17810.2. PMID: 38376830.

b) International conferences:

4

1. Á. López-Valiñas, Marta Valle, Marta Perez, A. Darji, C. Chiapponi, L. Ganges, J. Segalés and J.I. Núñez Genomic and evolutionary analysis of swine influenza A virus (H1N2) in challenged vaccinated pigs-EPIZONE 2023

2. C. Chiapponi, A. Prosperi, L. Soliani, A. De Mattia, C. Torreggiani, L. Baioni, I. Zanni, G. Guadagnini, E. Pileri, D. Ponzoni, A. Luppi UNDERSTANDING THE DYNAMICS AND EVOLUTION OF SWINE INFLUENZA VIRUSES IN EUROPE, ICRAD PIGIE: LONGITUDINAL STUDY IN ITALY- ESPHM 2024

3. G. Simon, E.M. Mateu De Antonio, H. Everett, C. Chiapponi, T. Harder, G. Dauphin, C. Fablet, P. Ryt-Hansen, G.E. Martin Valls, B. Mollet, L. Soliani, A. Graaf, S. Hervé, M. Viuf Agerlin, L. Coronado, S. Leetham, A. Luppi, K. Lillie-Jaschniski, S. Thiroux, G. Richard, C. Deblanc, M. Andraud, N. Rose, L.E. Larsen. UNDERSTANDING THE DYNAMICS AND EVOLUTION OF SWINE INFLUENZA VIRUSES IN ENDEMICALLY INFECTED PIG HERDS: COORDINATED LONGITUDINAL STUDIES IN SIX EUROPEAN

COUNTRIES. ESPHM 2024

4. Alice Prosperi, Laura Soliani, Laura Baioni, Camilla Torreggiani, Simona Perulli, Laura Fiorentini, Giovanni Pupillo, Annalisa Santi, Ana Moreno, Andrea Luppi, Chiara Chiapponi. INFLUENZA A VIRUS SURVEILLANCE IN DOMESTIC AND WILD SUIDAE IN EMILIA-ROMAGNA REGION (NORTHERN ITALY). SISVET 2023

c) National conferences:

1

1. C. Chiapponi, A. Prosperi, L. Soliani, I. Zanni, A. De Mattia, L. Baioni, A. Mescoli, G. Guadagnini, D. Ponzoni, E. Pileri, C. Torreggiani, A. Luppi. APPROCCIO DIAGNOSTICO, MOLECOLARE E SIEROLOGICO, PER LO STUDIO DELLA DINAMICA DI CIRCOLAZIONE DI VIRUS INFLUENZALI SUINI IN DUE AZIENDE ENDEMICAMENTE INFETTE IN NORD ITALIA. SIDILV 2023

d) Other (Provide website address or link to appropriate information):

TOR7: SCIENTIFIC AND TECHNICAL TRAINING

17. Did your laboratory provide scientific and technical training to laboratory personnel from other WOA Members?

Yes

a) Technical visit : 3

b) Seminars : 1

c) Hands-on training courses: 0

d) Internships (>1 month) 0

| Type of technical training provided (a, b, c or d) | Country of origin of the expert(s) provided with training | No. participants from the corresponding country |
|----------------------------------------------------|-----------------------------------------------------------|-------------------------------------------------|
| A | GREECE | 1 |
| A | CYPRUS | 1 |
| A | ROMANIA | 1 |
| B | KOSOVO | 3 |

TOR8: QUALITY ASSURANCE

18. Does your laboratory have a Quality Management System?

Yes

| Quality management system adopted | Certificate scan (PDF, JPG, PNG format) | |
|-----------------------------------|-----------------------------------------|------------------------|
| UNI CEI EN ISO/IEC 17025:2018 | certificate PDF | Accreditation-cert.pdf |

19. Is your quality management system accredited?

Yes

| Test for which your laboratory is accredited | Accreditation body |
|----------------------------------------------|--------------------|
| Matrix (M) gene PCR | ILAC-MRA_Accredia |

20. Does your laboratory maintain a "biorisk management system" for the pathogen and the disease concerned?

Yes

The laboratory works according to the Manual of Diagnostic Tests and Vaccines for Terrestrial Animals, Chapter 1.1.4 and WHO Laboratory biosafety manual.

TOR9: SCIENTIFIC MEETINGS

21. Did your laboratory organise scientific meetings related to the pathogen in question on behalf of WOA?

No

22. Did your laboratory participate in scientific meetings related to the pathogen in question on behalf of WOA?

No

TOR10: NETWORK WITH WOAHP REFERENCE LABORATORIES

23. Did your laboratory exchange information with other WOAHP Reference Laboratories designated for the same pathogen or disease?

Yes

24. Do you network (collaborate or share information) with other WOAHP Reference Laboratories designated for the same pathogen?

Yes

| NETWORK/DISEASE | ROLE OF YOUR LABORATORY (PARTICIPANT, ORGANISER, ETC) | NO. PARTICIPANTS | PARTICIPATING WOAHP REF. LABS |
|---------------------------------------------------------------------------------|----------------------------------------------------------|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ESFLU COST Action | Participant | 36 | WOAHP reference Laboratory for swine influenza (APHA , UK) |
| ICRAD PIGIE | Participant | 6 | WOAHP reference Laboratory for swine influenza (APHA , UK) |
| OIE Terrestrial Manual, ninth edition: Chapter on Influenza A virus of swine | participant | 4 | WOAHP reference Laboratory for swine influenza (APHA , UK) National Veterinary Services Laboratories, DB, VS, APHIS, USDA National Institute of Animal Health-Ibaraki, Japan |

25. Did you organise or participate in inter-laboratory proficiency tests with WOAHP Reference Laboratories designated for the same pathogen?

No

26. Did your laboratory collaborate with other WOAHP Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

Yes

| TITLE OF THE PROJECT OR CONTRACT | SCOPE | NAME(S) OF RELEVANT WOAHP REFERENCE LABORATORIES |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------|
| Understanding the dynamics and evolution of swine influenza viruses in Europe: relevance for improved intervention and sustainable pig production-PIGIE (ICRAD) | ICRAD Research Area 1: Improved understanding of epidemic and emerging infectious animal diseases | WOAHP reference Laboratory for swine influenza (APHA , UK) |
| COST Action CA21132, European Swine Influenza Network (ESFLU) | ESFLU gathers 76 experts in an interdisciplinary One Health approach. The Action will advance scientific knowledge concerning swIAV, improve disease surveillance and management capabilities, benefit pork production and reduce risks to both animal and human health. | WOAHP reference Laboratory for swine influenza (APHA , UK) |

TOR11: OTHER INTERLABORATORY PROFICIENCY TESTING

27. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than WOAHP Reference Laboratories for the same pathogen?

Yes

| Purpose for inter-laboratory test comparisons ¹ | Role of your reference laboratory (organizer/participant) | No. participating laboratories | Name of the Test | WOAHP Member Countries |
|------------------------------------------------------------|-----------------------------------------------------------|--------------------------------|------------------------------|------------------------|
| Detection of influenza A virus by molecular test | participant | 17 | Influenza A detection by PCR | ITALY, |

TOR12: EXPERT CONSULTANTS

28. Did your laboratory place expert consultants at the disposal of WOAHP?

Yes

| KIND OF CONSULTANCY | Location | SUBJECT (FACULTATIVE) |
|-----------------------------------------------------------------------------------------------------|----------|----------------------------------------------------------------|
| Review of the Chapter 3.9.7. of the Manual of Diagnostic Tests and Vaccines for Terrestrial Animals | online | TERRESTRIAL MANUAL CHAPTER 3.9.7. INFLUENZA A VIRUSES OF SWINE |

29. Additional comments regarding your report:

No